[go: up one dir, main page]

TR199701713T1 - Hepatitis C a��lar�. - Google Patents

Hepatitis C a��lar�.

Info

Publication number
TR199701713T1
TR199701713T1 TR97/01713T TR9701713T TR199701713T1 TR 199701713 T1 TR199701713 T1 TR 199701713T1 TR 97/01713 T TR97/01713 T TR 97/01713T TR 9701713 T TR9701713 T TR 9701713T TR 199701713 T1 TR199701713 T1 TR 199701713T1
Authority
TR
Turkey
Prior art keywords
hepatitis
oil
water emulsion
lar
immunogenic derivative
Prior art date
Application number
TR97/01713T
Other languages
Turkish (tr)
Inventor
Cabezon Silva Teresa
Marie Momin Patricia
Marie-Josephe Claude Garcon Nathal�E
Original Assignee
Smithkline Beecham Biologicals S.A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biologicals S.A filed Critical Smithkline Beecham Biologicals S.A
Publication of TR199701713T1 publication Critical patent/TR199701713T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Bir asi kompozisyonu olup, QS21,3 De-O-asillen- dirilmis monofosforil lipid A (3D-MPL), bir su içinde yag emülsiyonundan olusmakta olup, burada su içinde yag emülsiyonu su bilesime sahiptir: skualen, alfa tokoferol ve tween 80 gibi bir metabolize edilebilir yag ve (a) bir hepatit C virüs çekirdek proteininden veya bunun bir imunojenik türevinden ve (b) bir hepatit C virüs envelop proteininden veya bunun bir imunojenik türevinden olusan gruptan seçilen en az bir imunojen.It is an acid composition, the QS21,3 De-O-acylated-monophosphoryl lipid A (3D-MPL), which consists of an oil-in-water emulsion, where the oil-in-water emulsion has a water composition: squalene, alpha tocopherol and tween 80. metabolizable oil and at least one immunogen selected from (a) a hepatitis C virus core protein or an immunogenic derivative thereof and (b) a group consisting of a hepatitis C virus envelop protein or an immunogenic derivative thereof.

TR97/01713T 1995-06-29 1996-06-20 Hepatitis C a��lar�. TR199701713T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9513261.9A GB9513261D0 (en) 1995-06-29 1995-06-29 Vaccines

Publications (1)

Publication Number Publication Date
TR199701713T1 true TR199701713T1 (en) 1998-05-21

Family

ID=10776867

Family Applications (1)

Application Number Title Priority Date Filing Date
TR97/01713T TR199701713T1 (en) 1995-06-29 1996-06-20 Hepatitis C a��lar�.

Country Status (15)

Country Link
EP (1) EP0835318A2 (en)
JP (1) JPH11508769A (en)
KR (1) KR19990028505A (en)
AU (1) AU6304996A (en)
BR (1) BR9609258A (en)
CA (1) CA2222456A1 (en)
CZ (1) CZ422397A3 (en)
GB (1) GB9513261D0 (en)
HU (1) HUP9901901A3 (en)
IL (1) IL122589A0 (en)
NO (1) NO976060L (en)
PL (1) PL324906A1 (en)
TR (1) TR199701713T1 (en)
WO (1) WO1997001640A2 (en)
ZA (1) ZA965459B (en)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0909323B1 (en) 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Helicobacter pylori bacterioferritin
US5858389A (en) * 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
AT405939B (en) * 1997-02-24 1999-12-27 Immuno Ag METHOD FOR INACTIVATING LIPID-ENVIRONED VIRUSES
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
EP1105496B1 (en) * 1998-08-21 2007-03-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Modified hcv peptide vaccines
PT1126876E (en) 1998-10-16 2007-04-30 Glaxosmithkline Biolog Sa Adjuvant systems and vaccines
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
AU772617B2 (en) * 1999-11-19 2004-05-06 Csl Limited Vaccine compositions
EP2189473A3 (en) 2000-10-27 2010-08-11 Novartis Vaccines and Diagnostics S.r.l. Nucleic and proteins from streptococcus groups A & B
US7776523B2 (en) 2000-12-07 2010-08-17 Novartis Vaccines And Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
WO2003070909A2 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
WO2002051233A2 (en) * 2002-03-04 2002-07-04 Zagyansky, Yuly Universal antimicrobial treatment
EP1532161B1 (en) 2002-06-13 2012-02-15 Novartis Vaccines and Diagnostics, Inc. Vectors for expression of hml-2 polypeptides
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
PT2351579T (en) 2002-10-11 2016-12-22 Novartis Vaccines And Diagnostics S R L Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2514328C (en) 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
ATE437633T2 (en) 2003-06-02 2009-08-15 Novartis Vaccines & Diagnostic IMMUNOGENIC COMPOSITIONS BASED ON BIODEGRADABLE MICROPARTICLES CONTAINING A DIPHTHERIA AND A TETANUST OXOID
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
PL1961426T3 (en) 2003-10-02 2012-03-30 Gsk Vaccines S R L Combined meningitis vaccines
JP5600375B2 (en) 2004-03-09 2014-10-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Influenza virus vaccine
WO2005105140A2 (en) 2004-04-30 2005-11-10 Chiron Srl Meningococcal conjugate vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
EP1766034B1 (en) 2004-05-21 2014-03-19 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for influenza virus vaccines
EP2277595A3 (en) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
WO2006078318A2 (en) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
NZ555937A (en) 2005-01-27 2009-05-31 Childrens Hosp & Res Ct Oak GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
WO2006089264A2 (en) 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
CA2626253A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
ES2376492T3 (en) 2006-03-23 2012-03-14 Novartis Ag IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS.
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
ES2561483T3 (en) 2007-09-12 2016-02-26 Glaxosmithkline Biologicals Sa GAS57 mutant antigens and GAS57 antibodies
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
PT2235046E (en) 2007-12-21 2012-10-26 Novartis Ag Mutant forms of streptolysin o
RU2475496C2 (en) 2008-02-21 2013-02-20 Новартис Аг MENINGOCOCCAL fHBP POLYPEPTIDES
WO2009114485A2 (en) 2008-03-10 2009-09-17 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
CN102245198B (en) 2008-12-09 2016-08-17 辉瑞疫苗有限责任公司 IgE CH3 peptide vaccine
WO2010079464A1 (en) 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
ES2733084T3 (en) 2009-03-06 2019-11-27 Glaxosmithkline Biologicals Sa Chlamydia antigens
KR20120034612A (en) 2009-04-14 2012-04-12 노파르티스 아게 Compositions for immunising against staphylococcus aureus
ES2552153T3 (en) 2009-04-30 2015-11-26 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
EP2944320A1 (en) 2009-06-15 2015-11-18 National University of Singapore Influenza vaccine, composition, and methods of use
CA2767536A1 (en) 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
MX2012000734A (en) 2009-07-16 2012-01-27 Novartis Ag Detoxified escherichia coli immunogens.
AU2010277254B2 (en) 2009-07-30 2015-05-07 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
EP2470204B1 (en) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
EP2865752A1 (en) 2009-09-03 2015-04-29 Pfizer Vaccines LLC PCSK9 vaccine
JP2013504556A (en) 2009-09-10 2013-02-07 ノバルティス アーゲー Combination vaccine for respiratory tract disease
NZ598645A (en) * 2009-09-10 2014-07-25 Merial Ltd New vaccine formulations comprising saponin-containing adjuvants
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
US20130022639A1 (en) 2009-09-30 2013-01-24 Novartis Ag Expression of meningococcal fhbp polypeptides
WO2011138636A1 (en) 2009-09-30 2011-11-10 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
EP2493499A1 (en) 2009-10-27 2012-09-05 Novartis AG Modified meningococcal fhbp polypeptides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
CA2785585A1 (en) 2009-12-22 2011-06-30 Celldex Therapeutics, Inc. Vaccine compositions
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
CN102834410B (en) 2010-03-30 2016-10-05 奥克兰儿童医院及研究中心 Modified factor H binding proteins (FHBP) and methods of use thereof
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
JP2013529894A (en) 2010-04-07 2013-07-25 ノバルティス アーゲー Method for generating parvovirus B19 virus-like particles
CN102933267B (en) 2010-05-28 2015-05-27 泰特里斯在线公司 Interactive hybrid asynchronous computer game infrastructure
US8895017B2 (en) 2010-06-07 2014-11-25 Pfizer Inc. HER-2 peptides and vaccines
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
WO2012006293A1 (en) 2010-07-06 2012-01-12 Novartis Ag Norovirus derived immunogenic compositions and methods
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
US9550811B2 (en) 2010-12-02 2017-01-24 Bionor Immuno As Peptide scaffold design
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
MX346475B (en) 2011-01-06 2017-03-22 Bionor Immuno As Monomeric and multimeric immunogenic peptides.
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
WO2013016460A1 (en) 2011-07-25 2013-01-31 Novartis Ag Compositions and methods for assessing functional immunogenicity of parvovirus vaccines
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
WO2013038375A2 (en) 2011-09-14 2013-03-21 Novartis Ag Methods for making saccharide-protein glycoconjugates
CN103930436A (en) 2011-09-14 2014-07-16 诺华股份有限公司 Escherichia coli vaccine combination
US9694063B2 (en) 2011-12-08 2017-07-04 Glaxosmithkline Biologicals Sa Clostridium difficile toxin-based vaccine
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
JP2015509713A (en) 2012-02-24 2015-04-02 ノバルティス アーゲー Pili protein and composition
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
EP3804749A3 (en) 2012-04-26 2021-07-28 GlaxoSmithKline Biologicals S.A. Antigens and antigen combinations
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
MX376235B (en) 2012-05-04 2025-03-07 Pfizer PROSTATE-ASSOCIATED ANTIGENS AND VACCINE-BASED IMMUNOTHERAPY REGIMEN.
AU2013265336A1 (en) 2012-05-22 2014-12-04 Novartis Ag Meningococcus serogroup X conjugate
NZ702146A (en) 2012-06-06 2016-11-25 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
AU2013320313B2 (en) 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
CN105307684A (en) 2012-10-02 2016-02-03 葛兰素史密丝克莱恩生物有限公司 Nonlinear saccharide conjugates
AR092896A1 (en) 2012-10-03 2015-05-06 Novartis Ag IMMUNOGENIC COMPOSITIONS
EP2925355B1 (en) 2012-11-30 2017-11-15 GlaxoSmithKline Biologicals S.A. Pseudomonas antigens and antigen combinations
AU2014385320B2 (en) 2013-05-15 2019-10-10 The Governors Of The University Of Alberta E1E2 HCV vaccines and methods of use
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN110859957B (en) 2014-01-21 2024-04-12 辉瑞公司 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
CA2955802C (en) 2014-07-23 2023-10-31 Children's Hospital & Research Center At Oakland Factor h binding protein variants and methods of use thereof
IL252915B2 (en) 2015-01-15 2024-04-01 Pfizer Immunogenic preparations for use in pneumococcal vaccines
JP2018521016A (en) 2015-06-03 2018-08-02 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ IL-23-p19 vaccine
CN107849119A (en) 2015-07-07 2018-03-27 阿费里斯股份公司 For the vaccine for the disease for treating and preventing IgE mediations
TWI720448B (en) 2015-07-21 2021-03-01 美商輝瑞股份有限公司 Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CA2996383A1 (en) 2015-08-25 2017-03-02 Nancy GUPTA Immunomodulatory compositions and methods of use thereof
EP3359577A4 (en) 2015-10-08 2019-04-17 The Governors of the University of Alberta HEPATITIS C VIRUS E1 / E2 HETERODIMERS AND METHODS OF PRODUCING THE SAME
EP3377098A1 (en) 2015-11-20 2018-09-26 Pfizer Inc Immunogenic compositions for use in pneumococcal vaccines
PL3405212T3 (en) 2016-01-19 2020-11-16 Pfizer Inc. Cancer vaccines
RU2762723C2 (en) 2017-01-20 2021-12-22 Пфайзер Инк. Immunogenic compositions for use in pneumococcal vaccines
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
US20210220462A1 (en) 2018-08-23 2021-07-22 Glaxosmithkline Biologicals Sa Immunogenic proteins and compositions
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
AU2018449744A1 (en) 2018-11-16 2021-05-27 Versitech Limited Live attenuated influenza B virus compositions methods of making and using thereof
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP7239509B6 (en) 2019-02-22 2023-03-28 ファイザー・インク Method for purifying bacterial polysaccharides
EP3952906A1 (en) 2019-04-10 2022-02-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
MX2022005252A (en) 2019-11-01 2022-06-08 Pfizer Escherichia coli compositions and methods thereof.
AU2021211012A1 (en) 2020-01-24 2022-08-25 Aim Immunotech Inc. Methods, compositions, and vaccines for treating a virus infection
EP4103587A1 (en) 2020-02-14 2022-12-21 Immunor AS Corona virus vaccine
JP2021132644A (en) 2020-02-21 2021-09-13 ファイザー・インク Purification of sugar
WO2021165928A2 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
EP4114848A4 (en) 2020-02-26 2024-04-03 Versitech Limited Pd-1-based vaccines against coronavirus infection
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2022090893A2 (en) 2020-10-27 2022-05-05 Pfizer Inc. Escherichia coli compositions and methods thereof
AU2021373358A1 (en) 2020-11-04 2023-06-01 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CA3200968A1 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
WO2022178196A1 (en) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
PH12023553205A1 (en) 2021-05-28 2024-02-19 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3221075A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023092090A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
AU2023207315A1 (en) 2022-01-13 2024-06-27 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20250163484A1 (en) 2022-02-25 2025-05-22 Pfizer Inc. Methods for Incorporating Azido Groups in Bacterial Capsular Polysaccharides
US20250312433A1 (en) 2022-05-11 2025-10-09 Pfizer Inc. Process for Producing of Vaccine Formulations With Preservatives
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL321069A (en) 2022-12-01 2025-07-01 Pfizer Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2049679C (en) * 1990-08-24 2005-06-21 Sushil G. Devare Hepatitis c assay utilizing recombinant antigens
DE4041304A1 (en) * 1990-12-21 1992-06-25 Mikrogen Molekularbiol Entw POLYPEPTIDES DERIVED FROM STRUCTURAL PROTEINS OF HEPATITIS C-VIRUS, TEST KITS CONTAINING THESE POLYPEPTIDES AND VACCINE AGAINST INFECTIONS FROM HEPATITIS C VIRUSES
JP3516681B2 (en) * 1991-06-24 2004-04-05 カイロン コーポレイション Hepatitis C virus (HCV) polypeptide
MY111880A (en) * 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
AU661404B2 (en) * 1992-06-25 1995-07-20 Smithkline Beecham Biologicals (Sa) Vaccine composition containing adjuvants
JPH06279500A (en) * 1992-09-30 1994-10-04 Imuno Japan:Kk Hbc fused protein particle and its production
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines

Also Published As

Publication number Publication date
WO1997001640A2 (en) 1997-01-16
IL122589A0 (en) 1998-06-15
NO976060D0 (en) 1997-12-23
JPH11508769A (en) 1999-08-03
AU6304996A (en) 1997-01-30
HUP9901901A3 (en) 2000-03-28
CZ422397A3 (en) 1998-06-17
CA2222456A1 (en) 1997-01-16
KR19990028505A (en) 1999-04-15
ZA965459B (en) 1997-04-01
PL324906A1 (en) 1998-06-22
MX9710523A (en) 1998-09-30
EP0835318A2 (en) 1998-04-15
HUP9901901A2 (en) 1999-09-28
GB9513261D0 (en) 1995-09-06
WO1997001640A3 (en) 1997-05-15
BR9609258A (en) 1999-05-11
NO976060L (en) 1998-02-17

Similar Documents

Publication Publication Date Title
TR199701713T1 (en) Hepatitis C a��lar�.
NO871057L (en) PROCEDURE FOR REDUCING PERMEABILITY IN AN OIL BEARING FORM.
DE59003557D1 (en) OMEGA-3 FATTY ACID FAT EMULSION FOR INTRAPERITONEAL APPLICATION, THEIR PRODUCTION AND APPLICATION.
ES2016585B3 (en) POLYBUTYLAMINS AND POLYISBUTYLAMINES, PROCEDURE FOR THE PREPARATION AND COMBUSTIBLE AND LUBRICANT COMPOSITIONS CONTAINING THESE SUBSTANCES.
TR25422A (en) REDUCED HEALED OIL COMPOSITIONS CONTAINING POLIOL POLIESTERS AND REDUCED CALORED TRIGLISERIDES.
DE3787118D1 (en) Fluorine, water and oil repellent preparation.
NO863527L (en) PROCEDURE FOR PREPARING AN EMULSION OF OIL IN WATER.
AR012049A2 (en) METHOD FOR PREPARING AN EMULSIONING COMPOSITION POSSESSING EMULSIONING PROPERTIES ENHANCED IN AN OIL-IN-WATER OR WATER-IN-OIL EMULSION, AND EMULSING COMPOSITION PREPARED BY SUCH METHOD
IS4265A (en) Derivatives of mycophenolic acids having a N-atom-linked group at position 6
DE69131636D1 (en) (6,7-substituted-8-alkoxy-1-cyclopropyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid-03.04) -bis (acyloxy-0) -borates and their salts and methods for their preparation
DE3670577D1 (en) OIL IN WATER EMULSION.
DE3684458D1 (en) AEROSTATIC BEARING AND ITS MANUFACTURING METHOD.
DE69019805D1 (en) Water-in-oil emulsion.
FI890510L (en) Emulsion composition containing amphipathic emulsifiers and method of preparation thereof
BR8905322A (en) COMBINED RADIAL AND ANCHOR BEARINGS
DE69425948D1 (en) Composition with improved water solubility, containing a water-insoluble or water-insoluble compound
NO972219D0 (en) immunogen
DE69732436D1 (en) SYRUPE AND MADE OF EMULSION CONTAINING EMULSION
IT8919993A0 (en) CONCENTRATED COMPOSITION OF PHOTOGRAPHIC DEVELOPMENT AND METHOD FOR PREPARING IT.
IT222574Z2 (en) AUTOMATIC DISTRIBUTOR OF NEWSPAPERS, MAGAZINES AND SIMILAR.
DE3773140D1 (en) HYDRODYNAMIC BEARING.
ATE76557T1 (en) OIL-IN-WATER EMULSION.
DE69023488D1 (en) DETERMINATION OF FREE FATTY ACIDS.
GB8728955D0 (en) Improved water-in-oil emulsion explosive compositions & method for manufacture thereof
ES2100676T3 (en) SELF-GLOSSING NEUTRAL EMULSION FOR SOIL MAINTENANCE (III).